Yeah, whilst @bridog 's points are sensible, the company gave the distinct impression we would be aware of data by now. Personally I am sick to death of bio-techs talking up time lines and results. Investing without irrational exuberance is hard enough, without companies talking things up.
I have full confidence in MSB eventually getting partnerships and results, but I think SI has learnt he needs to pipe down a bit so we will have to wait. His comments about continued high mortality in cohorts during the ARDS trials were not helpful. I suspect we will get full ARdS data with a confirmation of Novartis' continued partnership in one announcement.
Deadline for Novartis, page-430
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.010(0.91%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.11 | $1.07 | $4.794M | 4.399M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 14500 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 141676 | 5 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |